Overview

Sustainable and Scalable Strategies for Safe and Effective Administration of Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma in Outpatient and Community Settings

Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.

Start Activity

Format

ActionED

Time to Complete

4.50 hr(s).

Release Date

April 10, 2026

Expires On

April 10, 2027

This educational activity is designed for community and academic hematologists/oncologists, as well as hematology/oncology clinical pharmacists, NPs and PAs in the oncology setting, oncology nurses and other members of the multidisciplinary rapid response team including members of the ED, ICU, and infectious disease teams in the community settings who care for/manage patients with R/R MM.

Multiple myeloma (MM) remains incurable. Despite advances in treatment and aggressive first-line therapy, most patients relapse. The pursuit for tolerable and effective treatments for heavily treated patients in the relapsed/refractory (R/R) setting has resulted in novel targets and therapies, including four bispecific antibodies (BsAbs).

Because these agents have unique adverse event profiles which can be life-threatening, patients are typically hospitalized during step-up dosing to ensure proper pretreatment, monitoring, and supportive care. Many institutions are piloting outpatient administration of BsAbs to increase access to, reduce inpatient hospitalizations, lower overall healthcare costs, and enhance patients’ experiences. Yet administration of BsAbs in community settings is challenged by lack of experience coupled with requirements for multidisciplinary care and poorly aligned infrastructures.

This activity supports community providers in assessing their infrastructure, protocols, and workforce to implement the clinical and operational elements necessary for safe and effective outpatient BsAb administration.

This activity also engages academic providers to support improved care coordination and transitions as well as mentoring of community specialists.

Upon completion of this activity, learners will be able to:

Community Oncology Sites:
• Align site infrastructure and build clinical capacity for safe and effective BsAb administration in community settings to address patient selection, step-up dosing criteria, treatment maintenance, and AE monitoring and management protocols
• Develop transition of care protocols to and from academic center providers to address referrals of eligible patients and outpatient administration of BsAbs
• Establish multidisciplinary care pathways, workflows, and training requirements to ensure optimal alignment to evidence-based care at each step in the treatment process

Individual multidisciplinary learners practicing in community settings:
• Integrate the latest evidence-based decision support tools and strategies to formulate individualized management plans for patients with R/R MM
• Employ strategies to prevent, monitor, and manage AEs associated with BsAbs
• Adopt patient-centric education and communication materials on BsAbs for the treatment of R/R MM

Individual hematologists/oncologists in academic settings:
• Foster a culture of mentorship and leadership to facilitate learning and optimal coordination of care between community and academic centers
• Develop transition of care protocols to outpatient community providers to address treatment maintenance and AE monitoring and management protocols

Provided by University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).

Supported by an educational grant provided by Johnson & Johnson.

Nazila Shafagati, MD
Clinical Associate of Medicine
University of Chicago
Chicago, IL

Benjamin Derman, MD

Associate Professor

Medicine, Section of Hematology/Oncology

University of Chicago

Chicago, IL

Brittany McArn, OPN-CG, CPPN

Financial Navigation Manager

Outpatient Oncology Services

FirstHealth of the Carolinas

Pinehurst, NC

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

The following financial relationships have been provided:

Nazila Shafagati, MD – Consultant: Current Health

Benjamin Derman, MD – Consultant: Canopy, Johnson & Johnson, Sanofi

Grants/Research Support: Amgen, GlaxoSmithKline

Review Panel Member: Bristol Myers Squibb

Brittany McArn, OPN-CG, CPPN – Nothing to disclose

The University of Chicago Pritzker School of Medicine, ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and The University of Chicago require the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: Novel combination approaches.

This activity will take up to 4.5 hours to complete. To receive credit, learners are required to complete the preassessment, view the online activity, complete action planning, the posttest, and the evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this enduring activity for a maximum of 4.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

Nora Eldasher
neldasher@achlcme.org

Overview

Sustainable and Scalable Strategies for Safe and Effective Administration of Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma in Outpatient and Community Settings

Intended Audience

Activity Purpose

Learning Objectives

Provider Information

Supporter Information

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities